Review



trampc1 cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC trampc1 cells
    AR inhibition increases T-cell cytotoxicity in vitro and in vivo . A, Expression of NY-ESO1 in C42B cells. B and C, NY-ESO1 -expressing C42B cells treated with either DMSO ( C ) or enzalutamide ( D ) for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days. D, NY-ESO1 -expressing C42B cells treated with enzalutamide for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days in the presence of an HLA-blocking antibody or control antibody. E and F, MHCI expression of WT or Ar -KD <t>TrampC1</t> cells without ( E ) or with ( F ) rIFNγ treatment. G, Schematic of in vivo TrampC1 tumor experiment. H, Tumor weights at time of harvest (day 12 posttumor implantation). I, Number of CD8 T cells in WT or Ar -KD TrampC1 tumors. J, Number of Nur77 -GFP+ T cells in WT or Ar -KD TrampC1 tumors. K, Representative cytograms showing CD44 and Spas1 tetramer staining in the tumor. Gated on live, TCRβ+, CD8 + . L, Number of Spas1 tetramer + CD8 T cells in the tumor. M, Representative cytograms showing CD44 and IFNγ expression in CD8 T cells in the tumor. Gated on live, TCRβ+, CD8 + . N, Number of IFNγ-expressing CD8 T cells in the tumor. O, Growth curves of WT and Ar -KD TrampC1 tumors in WT and Rag -KO animals. P, Tumor weights on day 29. Data representative of two to four independent experiments, with three to four animals per group for D – J and eight animals per group for K and L . For D–F , H , and J , unpaired two-tailed Student t test. For K and L , Two-way ANOVA, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Trampc1 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 233 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trampc1+cells/pmc11873725-120-0-5?v=ATCC
    Average 96 stars, based on 233 article reviews
    trampc1 cells - by Bioz Stars, 2026-07
    96/100 stars

    Images

    1) Product Images from "Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer"

    Article Title: Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

    Journal: Cancer Discovery

    doi: 10.1158/2159-8290.CD-24-0559

    AR inhibition increases T-cell cytotoxicity in vitro and in vivo . A, Expression of NY-ESO1 in C42B cells. B and C, NY-ESO1 -expressing C42B cells treated with either DMSO ( C ) or enzalutamide ( D ) for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days. D, NY-ESO1 -expressing C42B cells treated with enzalutamide for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days in the presence of an HLA-blocking antibody or control antibody. E and F, MHCI expression of WT or Ar -KD TrampC1 cells without ( E ) or with ( F ) rIFNγ treatment. G, Schematic of in vivo TrampC1 tumor experiment. H, Tumor weights at time of harvest (day 12 posttumor implantation). I, Number of CD8 T cells in WT or Ar -KD TrampC1 tumors. J, Number of Nur77 -GFP+ T cells in WT or Ar -KD TrampC1 tumors. K, Representative cytograms showing CD44 and Spas1 tetramer staining in the tumor. Gated on live, TCRβ+, CD8 + . L, Number of Spas1 tetramer + CD8 T cells in the tumor. M, Representative cytograms showing CD44 and IFNγ expression in CD8 T cells in the tumor. Gated on live, TCRβ+, CD8 + . N, Number of IFNγ-expressing CD8 T cells in the tumor. O, Growth curves of WT and Ar -KD TrampC1 tumors in WT and Rag -KO animals. P, Tumor weights on day 29. Data representative of two to four independent experiments, with three to four animals per group for D – J and eight animals per group for K and L . For D–F , H , and J , unpaired two-tailed Student t test. For K and L , Two-way ANOVA, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Figure Legend Snippet: AR inhibition increases T-cell cytotoxicity in vitro and in vivo . A, Expression of NY-ESO1 in C42B cells. B and C, NY-ESO1 -expressing C42B cells treated with either DMSO ( C ) or enzalutamide ( D ) for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days. D, NY-ESO1 -expressing C42B cells treated with enzalutamide for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days in the presence of an HLA-blocking antibody or control antibody. E and F, MHCI expression of WT or Ar -KD TrampC1 cells without ( E ) or with ( F ) rIFNγ treatment. G, Schematic of in vivo TrampC1 tumor experiment. H, Tumor weights at time of harvest (day 12 posttumor implantation). I, Number of CD8 T cells in WT or Ar -KD TrampC1 tumors. J, Number of Nur77 -GFP+ T cells in WT or Ar -KD TrampC1 tumors. K, Representative cytograms showing CD44 and Spas1 tetramer staining in the tumor. Gated on live, TCRβ+, CD8 + . L, Number of Spas1 tetramer + CD8 T cells in the tumor. M, Representative cytograms showing CD44 and IFNγ expression in CD8 T cells in the tumor. Gated on live, TCRβ+, CD8 + . N, Number of IFNγ-expressing CD8 T cells in the tumor. O, Growth curves of WT and Ar -KD TrampC1 tumors in WT and Rag -KO animals. P, Tumor weights on day 29. Data representative of two to four independent experiments, with three to four animals per group for D – J and eight animals per group for K and L . For D–F , H , and J , unpaired two-tailed Student t test. For K and L , Two-way ANOVA, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

    Techniques Used: Inhibition, In Vitro, In Vivo, Expressing, Transduction, Blocking Assay, Control, Staining, Two Tailed Test



    Similar Products

    trampc1 cells  (ATCC)
    96
    ATCC trampc1 cells
    AR inhibition increases T-cell cytotoxicity in vitro and in vivo . A, Expression of NY-ESO1 in C42B cells. B and C, NY-ESO1 -expressing C42B cells treated with either DMSO ( C ) or enzalutamide ( D ) for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days. D, NY-ESO1 -expressing C42B cells treated with enzalutamide for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days in the presence of an HLA-blocking antibody or control antibody. E and F, MHCI expression of WT or Ar -KD <t>TrampC1</t> cells without ( E ) or with ( F ) rIFNγ treatment. G, Schematic of in vivo TrampC1 tumor experiment. H, Tumor weights at time of harvest (day 12 posttumor implantation). I, Number of CD8 T cells in WT or Ar -KD TrampC1 tumors. J, Number of Nur77 -GFP+ T cells in WT or Ar -KD TrampC1 tumors. K, Representative cytograms showing CD44 and Spas1 tetramer staining in the tumor. Gated on live, TCRβ+, CD8 + . L, Number of Spas1 tetramer + CD8 T cells in the tumor. M, Representative cytograms showing CD44 and IFNγ expression in CD8 T cells in the tumor. Gated on live, TCRβ+, CD8 + . N, Number of IFNγ-expressing CD8 T cells in the tumor. O, Growth curves of WT and Ar -KD TrampC1 tumors in WT and Rag -KO animals. P, Tumor weights on day 29. Data representative of two to four independent experiments, with three to four animals per group for D – J and eight animals per group for K and L . For D–F , H , and J , unpaired two-tailed Student t test. For K and L , Two-way ANOVA, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Trampc1 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trampc1+cells/pmc11873725-120-0-5?v=ATCC
    Average 96 stars, based on 1 article reviews
    trampc1 cells - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    trampc1 cell line  (ATCC)
    96
    ATCC trampc1 cell line
    AR inhibition increases T-cell cytotoxicity in vitro and in vivo . A, Expression of NY-ESO1 in C42B cells. B and C, NY-ESO1 -expressing C42B cells treated with either DMSO ( C ) or enzalutamide ( D ) for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days. D, NY-ESO1 -expressing C42B cells treated with enzalutamide for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days in the presence of an HLA-blocking antibody or control antibody. E and F, MHCI expression of WT or Ar -KD <t>TrampC1</t> cells without ( E ) or with ( F ) rIFNγ treatment. G, Schematic of in vivo TrampC1 tumor experiment. H, Tumor weights at time of harvest (day 12 posttumor implantation). I, Number of CD8 T cells in WT or Ar -KD TrampC1 tumors. J, Number of Nur77 -GFP+ T cells in WT or Ar -KD TrampC1 tumors. K, Representative cytograms showing CD44 and Spas1 tetramer staining in the tumor. Gated on live, TCRβ+, CD8 + . L, Number of Spas1 tetramer + CD8 T cells in the tumor. M, Representative cytograms showing CD44 and IFNγ expression in CD8 T cells in the tumor. Gated on live, TCRβ+, CD8 + . N, Number of IFNγ-expressing CD8 T cells in the tumor. O, Growth curves of WT and Ar -KD TrampC1 tumors in WT and Rag -KO animals. P, Tumor weights on day 29. Data representative of two to four independent experiments, with three to four animals per group for D – J and eight animals per group for K and L . For D–F , H , and J , unpaired two-tailed Student t test. For K and L , Two-way ANOVA, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Trampc1 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trampc1+cells/pm39443797-416-0-6?v=ATCC
    Average 96 stars, based on 1 article reviews
    trampc1 cell line - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    trampc1 murine prostate cancer cell lines trampc1 cells  (ATCC)
    96
    ATCC trampc1 murine prostate cancer cell lines trampc1 cells
    AR inhibition increases T-cell cytotoxicity in vitro and in vivo . A, Expression of NY-ESO1 in C42B cells. B and C, NY-ESO1 -expressing C42B cells treated with either DMSO ( C ) or enzalutamide ( D ) for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days. D, NY-ESO1 -expressing C42B cells treated with enzalutamide for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days in the presence of an HLA-blocking antibody or control antibody. E and F, MHCI expression of WT or Ar -KD <t>TrampC1</t> cells without ( E ) or with ( F ) rIFNγ treatment. G, Schematic of in vivo TrampC1 tumor experiment. H, Tumor weights at time of harvest (day 12 posttumor implantation). I, Number of CD8 T cells in WT or Ar -KD TrampC1 tumors. J, Number of Nur77 -GFP+ T cells in WT or Ar -KD TrampC1 tumors. K, Representative cytograms showing CD44 and Spas1 tetramer staining in the tumor. Gated on live, TCRβ+, CD8 + . L, Number of Spas1 tetramer + CD8 T cells in the tumor. M, Representative cytograms showing CD44 and IFNγ expression in CD8 T cells in the tumor. Gated on live, TCRβ+, CD8 + . N, Number of IFNγ-expressing CD8 T cells in the tumor. O, Growth curves of WT and Ar -KD TrampC1 tumors in WT and Rag -KO animals. P, Tumor weights on day 29. Data representative of two to four independent experiments, with three to four animals per group for D – J and eight animals per group for K and L . For D–F , H , and J , unpaired two-tailed Student t test. For K and L , Two-way ANOVA, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Trampc1 Murine Prostate Cancer Cell Lines Trampc1 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trampc1+cells/pm38428412-653-3-14?v=ATCC
    Average 96 stars, based on 1 article reviews
    trampc1 murine prostate cancer cell lines trampc1 cells - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    trp53 inactivated prostate epithelial cells trampc1 cell line  (ATCC)
    96
    ATCC trp53 inactivated prostate epithelial cells trampc1 cell line
    AR inhibition increases T-cell cytotoxicity in vitro and in vivo . A, Expression of NY-ESO1 in C42B cells. B and C, NY-ESO1 -expressing C42B cells treated with either DMSO ( C ) or enzalutamide ( D ) for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days. D, NY-ESO1 -expressing C42B cells treated with enzalutamide for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days in the presence of an HLA-blocking antibody or control antibody. E and F, MHCI expression of WT or Ar -KD <t>TrampC1</t> cells without ( E ) or with ( F ) rIFNγ treatment. G, Schematic of in vivo TrampC1 tumor experiment. H, Tumor weights at time of harvest (day 12 posttumor implantation). I, Number of CD8 T cells in WT or Ar -KD TrampC1 tumors. J, Number of Nur77 -GFP+ T cells in WT or Ar -KD TrampC1 tumors. K, Representative cytograms showing CD44 and Spas1 tetramer staining in the tumor. Gated on live, TCRβ+, CD8 + . L, Number of Spas1 tetramer + CD8 T cells in the tumor. M, Representative cytograms showing CD44 and IFNγ expression in CD8 T cells in the tumor. Gated on live, TCRβ+, CD8 + . N, Number of IFNγ-expressing CD8 T cells in the tumor. O, Growth curves of WT and Ar -KD TrampC1 tumors in WT and Rag -KO animals. P, Tumor weights on day 29. Data representative of two to four independent experiments, with three to four animals per group for D – J and eight animals per group for K and L . For D–F , H , and J , unpaired two-tailed Student t test. For K and L , Two-way ANOVA, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Trp53 Inactivated Prostate Epithelial Cells Trampc1 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trampc1+cells/pm37055829-55-1-11?v=ATCC
    Average 96 stars, based on 1 article reviews
    trp53 inactivated prostate epithelial cells trampc1 cell line - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    prostate epithelial cells trampc1 cell line  (ATCC)
    96
    ATCC prostate epithelial cells trampc1 cell line
    AR inhibition increases T-cell cytotoxicity in vitro and in vivo . A, Expression of NY-ESO1 in C42B cells. B and C, NY-ESO1 -expressing C42B cells treated with either DMSO ( C ) or enzalutamide ( D ) for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days. D, NY-ESO1 -expressing C42B cells treated with enzalutamide for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days in the presence of an HLA-blocking antibody or control antibody. E and F, MHCI expression of WT or Ar -KD <t>TrampC1</t> cells without ( E ) or with ( F ) rIFNγ treatment. G, Schematic of in vivo TrampC1 tumor experiment. H, Tumor weights at time of harvest (day 12 posttumor implantation). I, Number of CD8 T cells in WT or Ar -KD TrampC1 tumors. J, Number of Nur77 -GFP+ T cells in WT or Ar -KD TrampC1 tumors. K, Representative cytograms showing CD44 and Spas1 tetramer staining in the tumor. Gated on live, TCRβ+, CD8 + . L, Number of Spas1 tetramer + CD8 T cells in the tumor. M, Representative cytograms showing CD44 and IFNγ expression in CD8 T cells in the tumor. Gated on live, TCRβ+, CD8 + . N, Number of IFNγ-expressing CD8 T cells in the tumor. O, Growth curves of WT and Ar -KD TrampC1 tumors in WT and Rag -KO animals. P, Tumor weights on day 29. Data representative of two to four independent experiments, with three to four animals per group for D – J and eight animals per group for K and L . For D–F , H , and J , unpaired two-tailed Student t test. For K and L , Two-way ANOVA, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Prostate Epithelial Cells Trampc1 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trampc1+cells/pm37055829-55-2-11?v=ATCC
    Average 96 stars, based on 1 article reviews
    prostate epithelial cells trampc1 cell line - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    AR inhibition increases T-cell cytotoxicity in vitro and in vivo . A, Expression of NY-ESO1 in C42B cells. B and C, NY-ESO1 -expressing C42B cells treated with either DMSO ( C ) or enzalutamide ( D ) for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days. D, NY-ESO1 -expressing C42B cells treated with enzalutamide for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days in the presence of an HLA-blocking antibody or control antibody. E and F, MHCI expression of WT or Ar -KD TrampC1 cells without ( E ) or with ( F ) rIFNγ treatment. G, Schematic of in vivo TrampC1 tumor experiment. H, Tumor weights at time of harvest (day 12 posttumor implantation). I, Number of CD8 T cells in WT or Ar -KD TrampC1 tumors. J, Number of Nur77 -GFP+ T cells in WT or Ar -KD TrampC1 tumors. K, Representative cytograms showing CD44 and Spas1 tetramer staining in the tumor. Gated on live, TCRβ+, CD8 + . L, Number of Spas1 tetramer + CD8 T cells in the tumor. M, Representative cytograms showing CD44 and IFNγ expression in CD8 T cells in the tumor. Gated on live, TCRβ+, CD8 + . N, Number of IFNγ-expressing CD8 T cells in the tumor. O, Growth curves of WT and Ar -KD TrampC1 tumors in WT and Rag -KO animals. P, Tumor weights on day 29. Data representative of two to four independent experiments, with three to four animals per group for D – J and eight animals per group for K and L . For D–F , H , and J , unpaired two-tailed Student t test. For K and L , Two-way ANOVA, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

    Journal: Cancer Discovery

    Article Title: Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

    doi: 10.1158/2159-8290.CD-24-0559

    Figure Lengend Snippet: AR inhibition increases T-cell cytotoxicity in vitro and in vivo . A, Expression of NY-ESO1 in C42B cells. B and C, NY-ESO1 -expressing C42B cells treated with either DMSO ( C ) or enzalutamide ( D ) for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days. D, NY-ESO1 -expressing C42B cells treated with enzalutamide for 14 days and then cocultured with CD8 T cells transduced with a NY-ESO1 TCR for 3 days in the presence of an HLA-blocking antibody or control antibody. E and F, MHCI expression of WT or Ar -KD TrampC1 cells without ( E ) or with ( F ) rIFNγ treatment. G, Schematic of in vivo TrampC1 tumor experiment. H, Tumor weights at time of harvest (day 12 posttumor implantation). I, Number of CD8 T cells in WT or Ar -KD TrampC1 tumors. J, Number of Nur77 -GFP+ T cells in WT or Ar -KD TrampC1 tumors. K, Representative cytograms showing CD44 and Spas1 tetramer staining in the tumor. Gated on live, TCRβ+, CD8 + . L, Number of Spas1 tetramer + CD8 T cells in the tumor. M, Representative cytograms showing CD44 and IFNγ expression in CD8 T cells in the tumor. Gated on live, TCRβ+, CD8 + . N, Number of IFNγ-expressing CD8 T cells in the tumor. O, Growth curves of WT and Ar -KD TrampC1 tumors in WT and Rag -KO animals. P, Tumor weights on day 29. Data representative of two to four independent experiments, with three to four animals per group for D – J and eight animals per group for K and L . For D–F , H , and J , unpaired two-tailed Student t test. For K and L , Two-way ANOVA, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

    Article Snippet: TrampC1 cells were purchased from ATCC (RRID:CVCL_3614).

    Techniques: Inhibition, In Vitro, In Vivo, Expressing, Transduction, Blocking Assay, Control, Staining, Two Tailed Test